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Abstract The thiazolidinedione troglitazone inhibits angioten-
sin II-induced extracellular signal-regulated kinase 1/2 mitogen-
activated protein kinase activity in vascular smooth muscle
cells. Activation of extracellular signal-regulated kinase 1/2 by
angiotensin II is a multistep process involving both its
phosphorylation by mitogen-activated protein kinase extracel-
lular signal-regulated kinase kinase in the cytoplasm and a
subsequent translocation to the nucleus. The cytoplasmic
activation of extracellular signal-regulated kinase 1/2 in vascular
smooth muscle cells proceeds through the protein kinase
CjCmitogen-activated protein kinase extracellular signal-regu-
lated kinase kinaseCextracellular signal-regulated kinase path-
way. Troglitazone did not affect the angiotensin II-induced
activation of protein kinase Cj or its downstream signaling
kinases extracellular signal-regulated kinase 1/2 in the cytosol.
In contrast, angiotensin II-induced activation of protein kinase
Cj and extracellular signal-regulated kinase 1/2 in the nucleus
were both inhibited by troglitazone. Nuclear translocation of
extracellular signal-regulated kinase 1/2 induced by angiotensin
II was completely blocked by troglitazone. Protein kinase Cj,
however, did not translocate upon angiotensin II stimulation.
Troglitazone, therefore, inhibits both angiotensin II-induced
nuclear translocation of extracellular signal-regulated kinase
1/2 and the nuclear activity of its upstream signaling kinase
protein kinase Cj. Since extracellular signal-regulated kinase 1/2
nuclear translocation may be a critical signaling step for multiple
growth factors that stimulate vascular smooth muscle cells
proliferation and migration, troglitazone may provide a new
therapeutical approach for the prevention and treatment of
atherosclerosis and restenosis.
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1. Introduction
Angiotensin II (AII) is an important regulator of multiple
vascular functions and contributes under pathological condi-
tions to alterations in the arterial wall by stimulating vascular
smooth muscle cell (VSMC) proliferation and migration [1,2].
These e¡ects of AII on VSMC are extracellular signal-regu-
lated kinase (ERK) 1/2-dependent and mediated via the AT-1
receptor [3,4]. Previously, we demonstrated that the thiazoli-
dinedione troglitazone (TRO) blocked AII-induced DNA syn-
thesis and migration in VSMCs by inhibiting ERK 1/2 acti-
vation [5]. TRO also inhibited bFGF-induced proliferation
and PDGF-directed migration through ERK 1/2-dependent
pathways [6]. In contrast to its action on the AII signaling
pathway, TRO did not a¡ect PDGF- or bFGF-induced ERK
1/2 activity [6], suggesting that TRO targets two or more
intracellular sites, which all ultimately result in a suppression
of ERK 1/2 signaling.
In VSMCs, signaling to ERK 1/2 by AII is mediated via its
G-protein-coupled seven domain transmembrane AT1 recep-
tor [7] while bFGF and PDGF induce signal transduction
through their tyrosine kinase receptors [8]. Activation of
ERK 1/2 in response to bFGF and PDGF is mediated
through the ras/raf/mitogen-activated protein kinase
(MAPK) ERK kinase (MEK)/ERK 1/2 signaling cascade
[9,10], whereas recent studies report that the atypical protein
kinase Cj (PKCj) can function as an upstream serine/threo-
nine kinase for AII-induced MEK and ERK 1/2 activation in
VSMCs [11]. In addition, several studies describe a nuclear
translocation of PKCj after growth factor stimulation [12^
14], where it phosphorylates intranuclear targets such as nu-
cleolin and potentially ERK 1/2 via MEK [15].
ERK 1/2 also translocates into the cell nucleus after growth
factor stimulation [16,17], where it phosphorylates and acti-
vates multiple transcription factors which modulate gene ex-
pression to regulate cell proliferation [18,19]. AII is known to
induce a prominent translocation of activated ERK 1/2 into
the cell nucleus of neuronal cells, where ERK 1/2 functions to
mediate nuclear events such as activation of the serum re-
sponse element (SRE), c-fos expression and an increased
AP1-binding activity [20]. Recent studies reporting the inhib-
ition of VSMC migration by the p21 cyclin-dependent kinase
inhibitor (Cip 1) and cyclin G1 antisense constructs suggest
that nuclear events are also required for migration [21,22].
This is in line with our ¢nding that migration of VSMCs
towards multiple growth factors is blocked by transcriptional
inhibition with actinomycin D [23].
TRO is a high a⁄nity ligand for peroxisome proliferator-
activated receptor Q (PPARQ) [24], a ligand-activated tran-
scription factor of the steroid hormone nuclear receptor
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superfamily [25]. An important objective of this study was to
determine whether TRO exerts its inhibitory e¡ects on AII-
induced signaling at a nuclear level or merely targets cytosolic
signaling events. To elucidate which steps in the ERK 1/2
signaling cascade are a¡ected, we investigated the e¡ects of
TRO on AII-induced activation of PKCj and ERK 1/2 in the
cytosolic and nuclear cell compartments.
2. Materials and methods
2.1. Materials
Materials were obtained from the following suppliers: Dulbecco’s
modi¢ed Eagle’s medium (DMEM), glutamine, antibiotics, HEPES,
DMSO, myelin basic protein (MBP) and monoclonal antibody against
smooth muscle K-actin from Sigma (St. Louis, MO, USA), AII was
from Bachem (Torrance, CA, USA), [Q-32P]ATP was from ICN (Ir-
vine, CA, USA), Hybond ECL nitrocellulose membrane, horseradish
peroxidase-linked anti-rabbit antibody, as well as ECL Western blot-
ting detection reagents were from Amersham Life Sciences (Arlington
Heights, IL, USA). Fetal bovine serum (FBS) was purchased from
Irvine Scienti¢c (Santa Ana, CA, USA). Sprague-Dawley rats were
from Charles River (MA, USA). The phospho-speci¢c- and total
ERK1/ERK2 ERK 1/2 rabbit antibodies were purchased from New
England BioLabs (Beverly, MA, USA). TRO was kindly provided by
Parke Davis (Ann Arbor, MI, USA). Antibodies against PKCj
were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA,
USA).
2.2. Cell culture
Rat aortic smooth muscle cells were prepared from thoracic aortas
of 2^3 month old Sprague-Dawley rats using the explant technique
[26]. The cells were cultured in DMEM containing 10% FBS,
150 mmol/l HEPES, 100 U/ml penicillin, 100 Wg/ml streptomycin
and 200 mmol/l glutamine. A monoclonal antibody against smooth
muscle K-actin was used to assess the purity of the smooth muscle cell
cultures. Flow cytometry of anti-smooth muscle K-actin antibody-
stained cells revealed a purity of 95 þ 3%. For all experiments, early
passaged (¢ve or less) VSMCs were grown to 60^70% con£uency
and made quiescent by serum starvation (0.4% FBS/DMEM) for at
least 24 h. When used, TRO was added 30 min prior to the addition
of AII. For all data shown, each individual experiment represented in
the n value was performed using an independent preparation of
VSMCs.
2.3. Western blot analysis
For protein analysis, cultured VSMCs were grown to 60^70% con-
£uency and then starved for 24 h in 0.4% FBS/DMEM. For inhibitor
studies, cells were pre-treated for 30 min with TRO (10 WM) or vehicle
(0.4% FBS/DMEM) alone, followed by the addition of AII (1 WM).
Cells were then washed twice with ice-cold PBS and lysed with radio-
immunoprecipitation (RIPA) bu¡er (20 mM Tris-HCl, pH 7.5, 1%
Triton X-100, 0.5% NP 40, 150 mM NaCl, 2.5 mM Na-pyrophos-
phate, 100 WM Na-orthovanadate, 1 mM EGTA, 1 mM EDTA,
1 mM PMSF, 10 mg/l leupeptin) for 20 min on ice. After allowing
the cells to thaw, they were scraped o¡ the dish and centrifuged
(14 000 rpm, 30 min at 4‡C). For some experiments, nuclear and
cytosolic fractions were prepared by the method of Dignam et al.
[27]. Protein concentrations were determined using the Bradford pro-
tein assay (Bio-Rad, San Diego, CA, USA). Equal amounts of protein
(30 Wg) were then separated by SDS-PAGE (7.5% standard gel) and
transferred to nitrocellulose membranes using a Bio-Rad transblotter.
Non-speci¢c binding was blocked by using 5% fat-free milk powder
and 0.1% Tween 20 in TBS. The membranes were incubated with
rabbit polyclonal antibodies that recognize ERK1 or ERK2 which
are phosphorylated on threonine 202 and tyrosine 204, i.e. ‘phospho
ERK/ERK2’, or PKCj protein. Antibodies were used at a concentra-
tion of 1:1000 for 1 h in blocking solution. Blots were washed three
times for 15 min in 0.1% Tween 20/TBS, incubated for another hour
with goat anti-rabbit horseradish peroxidase-conjugated antibodies
(1:1000) for 1 h and washed again before ¢nal development using
the ECL Western blotting detection system. All Western blot experi-
ments were repeated at least three times with a di¡erent cell prepara-
tion.
2.4. PKCj activity measurements
To measure PKCj activity, VSMCs were lysed in bu¡er A (2.5 mM
Na-pyrophosphate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
10 Wg/ml leupeptin, 1 mM PMSF, 20 mM Tris, pH 7.5, 1% Triton
X-100, 1 mM L-glycerolphosphate, 1 mM Na-orthovanadate) and
then £ash frozen on a dry ice-ethanol bath. After allowing the cells
to thaw, cells were scraped o¡ the dish, centrifuged at 14 000 rpm (4‡C
for 30 min) and protein concentrations were determined using the
Bradford protein assay (Bio-Rad Laboratories, Richmond, VA,
USA). Equal amounts of proteins (50 Wg) in 100 Wl bu¡er A were
incubated overnight with rabbit polyclonal antibodies (1:50) against
PKCj at 4‡C. Then, 40 Wl protein Sepharose G beads (Pharmacia
Biotech, Piscataway, NJ, USA) was added to each sample, followed
by incubation for 2 h at 4‡C. After that, the samples were centrifuged
at 14 000 rpm for 30 s, pellets were washed twice with bu¡er A and
then twice with bu¡er B (25 mM Tris-HCl, pH 7.5, 0.5 M LiCl) and
once in 25 mM Tris-HCl, pH 7.5. Beads were resuspended in 15 Wl
kinase bu¡er (50 mM Tris-HCl, pH 7.5, 5 mM MgCl2 and 25 WM
ATP) to which 5 Wg MBP (21 kDa) and [Q-32P]ATP (5 WCi) was
added. Samples were incubated for 30 min at room temperature.
Then, the kinase reaction was stopped by boiling samples for 5 min
in Laemmli sample bu¡er. Protein samples were then separated by
SDS-PAGE (12% standard gel), the gel was dried and then subjected
to autoradiography.
2.5. Statistics
Analysis of variance and paired or unpaired t tests were performed
for statistical analysis, as appropriate. P values less than 0.05 were
considered to be statistically signi¢cant. Data are expressed as
mean þ S.E.M.
3. Results
3.1. AII-induced activation of cytosolic PKCj is not a¡ected by
TRO
We have previously shown that TRO inhibits AII-induced
Fig. 1. TRO does not a¡ect the AII-induced cytosolic PKCj activ-
ity. Quiescent VSMCs were incubated with TRO (10 WM) for 30
min before AII (1 WM) was added. After stimulation with AII for
10 min or 2 h, cytosolic cell extracts were prepared and equal
amounts of protein (50 Wg) were immunoprecipitated with a PKCj
antibody. Kinase assays for PKCj activity were then performed as
described in Section 2 and samples were separated on 12% SDS-
PAGE gels. Phosphorylation of MBP (phospho-MBP) by PKCj
was determined by autoradiography. The autoradiogram shown is
representative of three experiments using di¡erent cell preparations.
Densitometric analysis was performed using the NIH Image pro-
gram 1.60 for Macintosh. The data were calculated in arbitrary
units and are expressed as mean þ S.E.M., * = P6 0.05 versus con-
trol.
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ERK 1/2 activation in VSMCs [5]. Since PKCj functions as
an upstream kinase that activates and phosphorylates MEK
[11,28,29], which in turn phosphorylates and activates ERK 1/
2, we examined the e¡ect of TRO on AII-induced PKCj
activity in the cytosol. Using an immune complex phospho-
rylation assay, we observed a constitutive PKCj activity in
cytosolic extracts from untreated controls, which was signi¢-
cantly increased after stimulation with AII at 10 min and 2 h
(by 1.45-fold and 1.62-fold over control, P6 0.05). Treatment
with TRO had no e¡ect on the basal or AII-induced cytosolic
PKCj activity (Fig. 1).
3.2. TRO inhibits the nuclear ERK 1/2 activity, but not its
cytosolic activation by AII
Our previous results on TRO’s inhibition of AII-induced
ERK 1/2 activation were obtained in whole cell extracts [5].
Studies in other cell types, however, have demonstrated that
AII can di¡erentially regulate the ERK 1/2 activity in cyto-
solic and nuclear compartments due to its stimulation of ERK
1/2 translocation to the nucleus [20]. We therefore next exam-
ined the e¡ect of TRO on cytosolic or nuclear AII-induced
ERK 1/2 activation.
AII induced a rapid and transient activation of cytosolic
ERK 1/2 at 10 min (by a 6.2 þ 0.6-fold over control,
P6 0.05) with a return to baseline levels at 2 h (Fig. 2).
TRO had no e¡ect on the activation of cytosolic ERK 1/2
by AII. In contrast, AII stimulated a marked increase in acti-
vated nuclear ERK 1/2 at 10 min (16-fold) and 2 h (5.7-fold)
which was dramatically inhibited by TRO (inhibition by 92
and 65%, respectively), indicating that TRO exerts its inhib-
itory e¡ects on ERK 1/2 signaling at a nuclear level.
3.3. TRO inhibits AII-induced nuclear translocation of
ERK 1/2 in VSMCs
Inhibition of AII-stimulated nuclear ERK 1/2 activity by
TRO could result either indirectly by preventing the nuclear
translocation of activated ERK 1/2 or directly by inhibiting
the activation of ERK 1/2 residing in the nucleus. We there-
fore investigated whether AII induces nuclear translocation of
ERK 1/2 in VSMCs, as it has been described in other cell
types, and whether TRO interferes with this process.
Nuclear translocation of ERK 1/2 was observed 10 min
after stimulation with AII (8 þ 2.5-fold over control,
P6 0.05), with a further accumulation of total nuclear ERK
1/2 protein after 2 h (15.5 þ 4-fold over control, P6 0.05)
(Fig. 3A). These data are consistent with reports on the
time-course of nuclear ERK 1/2 translocation in other cell
types [30,31]. The nuclear translocation of ERK 1/2 was ac-
companied by a concomittant decrease in the amount of cy-
tosolic total ERK 1/2 protein at the 2 h time-point.
TRO completely inhibited the nuclear translocation of
Fig. 2. TRO inhibits the activation of nuclear MAPK, but not its
cytosolic activation by AII. Quiescent VSMCs were incubated with
TRO (10 WM) for 30 min before AII (1 WM) was added. Cells were
then stimulated with AII for 10 min or 2 h, lysed and equal
amounts of protein (30 Wg) of nuclear and cytosolic cell extracts
were separated on 7.5% SDS-PAGE gels. Immunoblotting was per-
formed with a phospho-speci¢c ERK1/ERK2 MAPK antibody. The
Western blots shown are representatives of three experiments using
di¡erent cell preparations. The densitometric data are expressed as
mean þ S.E.M., * = P6 0.05 versus control, @ = P6 0.05 versus AII
alone for 10 min.
Fig. 3. TRO inhibits AII-induced nuclear translocation of ERK 1/2 in VSMCs, without a¡ecting total ERK 1/2 protein levels in whole cell ex-
tracts. (A) Cell treatment and sample preparation was performed as described in Fig. 2. Nuclear and cytosolic extracts were separated on 7.5%
SDS-PAGE gels, followed by immunoblotting with an antibody against total ERK1/ERK2 ERK 1/2. (B) Quiescent VSMCs were incubated
with TRO (10 WM) for 30 min prior to the addition of AII (1 WM). Cells were then incubated for 10 min or 2 h, lysed and whole cell extracts
were prepared. Equal amounts of protein (30 Wg) were separated on 7.5% SDS-PAGE gels and immunoblotted against total ERK1/ERK2
MAPK. The Western blots shown are representative for three experiments using di¡erent cell preparations. The densitometric data are ex-
pressed as mean þ S.E.M., * = P6 0.05 versus control, @ = P6 0.05 versus AII alone for 10 min, # = P6 0.05 versus AII alone for 2 h.
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ERK 1/2 (Fig. 3A), without a¡ecting the amount of ERK 1/2
protein in whole cell extracts (Fig. 3B). These results demon-
strate that the observed inhibitory e¡ect of TRO is due to the
blockade of nuclear translocation, but not downregulation of
ERK 1/2 protein levels.
3.4. TRO inhibits AII-stimulated nuclear PKCj activity
PKCj has been shown to translocate into the nucleus after
growth factor stimulation, where it phosphorylates nuclear
targets such as nucleolin [12^15]. PKCj, therefore, may func-
tion as a potential upstream signaling kinase for AII-stimu-
lated ERK 1/2 activity in both the cytoplasm and the nucleus.
In order to investigate whether TRO inhibits not only the
nuclear translocation of ERK 1/2 but possibly also the nu-
clear activation of ERK 1/2 by AII-induced PKCj, we exam-
ined the e¡ects of TRO on PKCj activity in the nuclear frac-
tion.
Examining PKCj activity with an immune complex phos-
phorylation assay, we found that PKCj is constitutively active
in the nucleus, as evidenced by the bands detected in unstimu-
lated controls (Fig. 4). This is consistent with previous obser-
vations of constitutive PKCj kinase activity in PKCj RNA
micro-injected oocytes [32] or insect cells expressing rat PKCj
[33]. Stimulation with AII caused an increase in the nuclear
PKCj activity at 10 min and 2 h by 1.31-fold and 1.47-fold,
that was completely blocked by TRO (all P6 0.05) (Fig. 4).
The inhibition of PKCj activity in the nuclear compartment
by TRO, however, was not related to an inhibition of the
PKCj movement from the cytoplasm to the nucleus, as was
the case for ERK 1/2 tra⁄cking. As shown in Fig. 5, PKCj is
present in the nuclear and cytosolic compartment of unstimu-
lated cells and does not translocate upon stimulation with
AII. Treatment with TRO had no e¡ect on the amount of
total cytosolic or nuclear PKCj protein.
These results indicate that TRO inhibits both AII-induced
nuclear translocation of ERK 1/2 and the nuclear activity of
its upstream signaling kinase, PKCj.
4. Discussion
The present investigation demonstrates that TRO inhibits
AII-induced nuclear translocation of ERK 1/2 and the kinase
activity of PKCj in the nucleus. The ERK1/2 MAPKs are
serine/threonine protein kinases which are required for the
mitogenic and chemotactic e¡ects of AII in VSMCs [3]. Nu-
clear translocation of activated ERK 1/2 is a critical event for
the ERK 1/2-dependent regulation of transcription factors
and other signaling molecules in the nucleus that modulate
cell behavior [18,19]. PKCj functions not only as an upstream
cytosolic kinase for AII-induced activation of the MEK/ERK
1/2 pathway [11], but can phosphorylate and activate nuclear
targets as well [15]. Thus, both kinases may be important for
regulating VSMC proliferation and migration by interacting
at cytosolic and nuclear levels to regulate the transduction of
AII-induced signals into the nucleus.
Our data reveal that TRO inhibits AII-induced ERK 1/2-
dependent signaling in VSMCs through e¡ects on multiple
targets. These ¢ndings may explain our previous observations
that TRO inhibited bFGF and PDGF signaling pathways in
VSMCs which regulate ERK 1/2-dependent cell functions, but
had no e¡ect on the ERK 1/2 activity induced by these growth
factors [6]. Similar to our ¢ndings in this study, the e¡ect of
TRO on PDGF and bFGF signaling may be due to an inhib-
ition of ERK 1/2 translocation into the nucleus, while the
total ERK 1/2 activity in response PDGF or bFGF signaling
through their tyrosine kinase receptors is una¡ected.
The partial inhibition of AII-induced ERK 1/2 activation
by TRO is likely due to its inhibition of the AII-stimulated
nuclear PKCj activity. Whereas TRO did not a¡ect the cyto-
solic PKCj activity and the consequent activation of cytosolic
ERK 1/2 after AII stimulation, it markedly inhibited the AII-
Fig. 4. TRO inhibits AII-stimulated nuclear PKCj activity. Quies-
cent VSMCs were treated as described in Fig. 1 and nuclear extracts
were prepared. After immunoprecipitation of equal amounts of pro-
tein (50 Wg) with a PKCj antibody, kinase assays for PKCj activity
were performed. Samples were then separated on 12% SDS-PAGE
gels and phosphorylation of MBP (phospho-MBP) by PKCj was
determined by autoradiography. The autoradiogram shown is repre-
sentative for three experiments using di¡erent cell preparations. Re-
sults of the densitometric analysis are depicted in the lower panel.
Data are expressed as mean þ S.E.M., * = P6 0.05 versus control,
@ = P6 0.05 versus AII alone for 10 min, # = P6 0.05 versus AII
alone for 2 h.
Fig. 5. Total PKCj protein is not a¡ected by TRO and does not
translocate to the nucleus after AII stimulation. Cell treatment and
sample preparation were performed as described in Fig. 2. Nuclear
and cytosolic extracts were separated on 7.5% SDS-PAGE gels, fol-
lowed by immunoblotting with an antibody against PKCj. The
Western blots shown are representative of three independently per-
formed experiments and the results of the densitometric analysis are
shown as mean þ S.E.M.
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induced nuclear PKCj activity. Although it has been reported
that PKCj can undergo nuclear translocation upon growth
factor stimulation [12^14], we did not observe a movement
of PKCj protein from the cytosol to the nucleus after stim-
ulation with AII. In our experimental conditions, PKCj was
expressed and constitutively active in both the cytosolic and
nuclear compartment, which is consistent with reports on oth-
er cell types [14,32^34]. Thus, unlike the e¡ect of TRO on
ERK 1/2 tra⁄cking, the inhibition of nuclear PKCj activity
is not due to an inhibition of translocation. PKCj is known to
activate MEK [11,28,29], which in turn leads to ERK 1/2
activation. Although there is no conclusive evidence that
this signaling cascade functions in the nucleus, mitogenic stim-
ulation of COS7 cells leads to a rapid nuclear translocation of
MEK [35]. Taken together, these data suggest a role for
PKCj in activating the nuclear ERK 1/2 protein, which could
explain the partial inhibition of AII-induced ERK 1/2 activa-
tion by TRO in whole cell extracts, that we have previously
reported [5].
Our ¢nding, that TRO inhibits the nuclear translocation of
ERK 1/2 and nuclear PKCj activity in response to AII, there-
by ultimately leading to an inhibition of nuclear ERK 1/2
activation, provides strong evidence that TRO speci¢cally tar-
gets nuclear ERK 1/2 signaling steps. A nuclear site of action
of TRO, however, is not unexpected since TRO is a known
ligand for PPARQ, a nuclear transcription factor of the steroid
hormone receptor superfamily [24,25]. Since PPARQ is mainly
localized in the nucleus of VSMCs [36], this receptor likely
mediates the nuclear e¡ects of TRO. Inhibition of signaling
through PPARQ is also consistent with our data showing that
TRO had no e¡ect on AII-induced cytosolic PKCj activation
or ERK 1/2 activity. A possible mechanism for an inhibition
of ERK 1/2 translocation by PPARQ could be due to protein-
protein interactions, as it has been shown for PPARQ-related
transrepression of the transcription factors NFkB and AP1 in
macrophages [37].
The inhibition of ERK 1/2-mediated phosphorylation of
nuclear proteins by TRO could constitute the mechanism by
which this agent blocks AII-induced VSMC growth and mi-
gration. This hypothesis is in line with the observed ability of
TRO to inhibit signaling through multiple growth factor path-
ways, which all converge at the activation of ERK 1/2 [5,23]
and may explain how TRO suppresses vascular lesion forma-
tion [6]. We and others have shown that TRO inhibits neo-
intima formation after balloon injury in non-diabetic [6] and
diabetic rats [38]. Similar vascular protective e¡ects have been
described for ACE inhibitors and AT1 receptor blockers in a
comparable rat model [1]. Moreover, a recent study empha-
sizes the importance of AII-induced ERK 1/2 activation in
vivo, where the rapid activation of ERK 1/2 in the rat aorta
after balloon injury was inhibited by a AT1 receptor blockade
and ACE inhibition [39]. However, clinical trials using ACE
inhibitors failed to prevent restenosis after coronary angio-
plasty in man [40,41]. These contrary results may be due, in
part, to the additional e¡ects of other growth factors involved
in vascular remodeling. By targeting nuclear ERK 1/2 trans-
location and activation, TRO may inhibit the critical signaling
steps common to the action of multiple growth factors, there-
by limiting the development and progression of restenotic and
atherosclerotic lesions.
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